NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio’s proprietary technology.
Read more at globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
XILIO THERAPEUTICS INC
NASDAQ:XLO (2/12/2025, 8:00:03 PM)
After market: 1.3501 -0.13 (-8.78%)1.48
+0.82 (+125.27%)
XLO Latest News and Analysis
8 hours ago - ChartmillKeep an eye on the top gainers and losers in Wednesday's session.Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
9 hours ago - ChartmillThese stocks are the most active in today's sessionLet's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session.
10 hours ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
12 hours ago - ChartmillTraders are paying attention to the gapping stocks in Wednesday's session.The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
